argenx reports Q3 2026 results and provides business update
FROM THE WIRE · FINANCE.YAHOO.COM
argenx SE Continued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth sBLA for VYVGART Hytrulo in IMNM on track for submission by year-end; pursuing additional registrational…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishStrong VYVGART sales growth and upcoming pipeline milestones are relevant for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01VYVGART generated $1.7 billion in global net sales, up 54% year over year.
- 02The sBLA for VYVGART Hytrulo in IMNM is on track for submission by year-end.
- 03Phase 3 MMN data for empasiprubart are expected in December 2026.
- 04FB102 is advancing to Phase 3 in celiac disease.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets